PD-L1 Expression in Lung Cancer.
Immunotherapies targeted against programmed death ligand 1 (PD-L1) and its receptor (PD-1) have improved survival in a subset of patients with advanced lung cancer. PD-L1 protein expression has emerged as a biomarker that predicts which patients are more likely to respond to immunotherapy. The understanding of PD-L1 as a biomarker is complicated by the history of use of different immunohistochemistry platforms with different PD-L1 antibodies, scoring systems, and positivity cut-offs for immunotherapy clinical trials with different anti-PD-L1 and anti-PD-1 drugs. Herein, we summarize the brief history of PD-L1 as a biomarker and describe the challenges remaining to harmonize PD-L1 detection and interpretation for best patient care.
Department of Medicine/Medical Oncology, University of Colorado Cancer Center, University of Colorado, Denver, Colorado.
Hui
H
Yu
Department of Medicine/Medical Oncology, University of Colorado Cancer Center, University of Colorado, Denver, Colorado; Department of Pathology, University of Colorado, Denver, Colorado; Department of Pathology, Moffitt Cancer Center, Tampa, Florida; Department of Thoracic Oncology, Moffitt Cancer Center, Tampa, Florida.
Theresa A
TA
Boyle
Department of Oncology, Shanghai Pulmonary Hospital, Shanghai, People's Republic of China.
Caicun
C
Zhou
Department of Pathology, Yale University, New Haven, Connecticut.
David L
DL
Rimm
Department of Medicine/Medical Oncology, University of Colorado Cancer Center, University of Colorado, Denver, Colorado; Department of Pathology, University of Colorado, Denver, Colorado. Electronic address: Fred.Hirsch@ucdenver.edu.
Fred R
FR
Hirsch
D000818:Animals; D060890:B7-H1 Antigen / Q000032:analysis* / Q000037:antagonists & inhibitors / Q000276:immunology; D015415:Biomarkers / Q000032:analysis; D006801:Humans; D007150:Immunohistochemistry; D007167:Immunotherapy; D008175:Lung Neoplasms / Q000737:chemistry* / Q000188:drug therapy; D051379:Mice
D060890:B7-H1 Antigen; D015415:Biomarkers; C423236:CD274 protein, human
Biomarker; Immunotherapy; Lung cancer; PD-L1